Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

APO-NAPRO-NA TABLET 275 MG [SIN07136P]

Active ingredients: APO-NAPRO-NA TABLET 275 MG

View product's general information
Last updated 24 April 2026

Product Info

APO-NAPRO-NA TABLET 275 MG

[SIN07136P]

Product information

Active Ingredient and Strength

NAPROXEN SODIUM - 275 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

APOTEX INC - CANADA

Registration Number

SIN07136P

Licence Holder

PHARMAFORTE SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

M01AE02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

Indications: For the relief of mild to moderately severe pain accompanied by inflammation in conditions such as musculoskeletal trauma and postdental extraction. Also indicated for the relief of pain associated with post partum cramping and dysmenorrhea.

Dosing

Dosage: The recommended starting dose of naproxen sodium for adults is two 275 mg tablets followed by one 275 mg tablet every 6 to 8 hours, as required. The total daily dose should not exceed 5 tablets (1375 mg).

Contraindications

Contraindications: Peptic ulcer or active inflammatory diseases of the gastrointestinal system.
Known or suspected hypersensitivity to the drug. Naproxen sodium should not be used in patients in whom acute asthmatic attacks, urticaria, rhinitis or other allergic manifestations are precipitated by ASA or other nonsteroidal anti-inflammatory agents. Fatal anaphylactoid reactions have occurred in such individuals.